• COVID-19
  • Biosimilars
  • Cataract Therapeutics
  • DME
  • Gene Therapy
  • Workplace
  • Ptosis
  • Optic Relief
  • Imaging
  • Geographic Atrophy
  • AMD
  • Presbyopia
  • Ocular Surface Disease
  • Practice Management
  • Pediatrics
  • Surgery
  • Therapeutics
  • Optometry
  • Retina
  • Cataract
  • Pharmacy
  • IOL
  • Dry Eye
  • Understanding Antibiotic Resistance
  • Refractive
  • Cornea
  • Glaucoma
  • OCT
  • Ocular Allergy
  • Clinical Diagnosis
  • Technology

Retinal assessment made easy by digital imaging

Article

Wakeforest, NC-Digital Healthcare Inc. has been approved by the U.S. Food and Drug Administration to pre-market its Retasure retinal risk assessment system and its iP technology platform.

Wakeforest, NC-Digital Healthcare Inc. has been approved by the U.S. Food and Drug Administration to pre-market its Retasure retinal risk assessment system and its iP technology platform.

Primary care physicians now can capture digital images of diabetic patients' retinas in a non-invasive procedure. The digital images are transmitted over a secure, HIPPA compliant network to a board certified ophthalmologist at an accredited reading center for examination and assessment.

Seven major contracts with primary diabetes care and ophthalmology providers have already been announced and general availability throughout the United States is being planned.

This system is unique because it can be operated by non-clinicians; it's non-invasive and requires no dilation; it obtains exceptionally high-quality digital images of the retina; it returns results quickly to primary care physicians; and it encourages patient compliance for regular retinal assessment.

Related Videos
© 2024 MJH Life Sciences

All rights reserved.